Dermatology News

The FDA has approved a supplemental new drug application for Zoryve expanding its indication to include treatment of psoriasis in pediatric patients, Arcutis Biotherapeutics announced in a press release.

Black race and male sex increased odds of palmoplantar psoriasis among pediatric patients, according to a study.

Numerous topical antiinfective products are available to your patients over-the-counter (OTC) or by prescription. Not only can the active antiinfective agents differ among these products, but their pharmaceutical dosage form (ie, ointment or cream) may as well. The indications for topical antiinfectives, including acne vulgaris, various fungal skin infections, or viral skin infections (eg, herpes simplex virus) are too broad to discuss in this column. Discussed in this month’s column will be the treatment of common bacterial skin infections, including impetigo, with topical antiinfectives.

Both methotrexate and cyclosporin are efficacious in the treatment of severe pediatric atopic dermatitis, but methotrexate showed higher rates of sustained treatment response, according to a study.

Roflumilast cream 0.05% achieved positive results in a pediatric trial of a phase 3 program treating children aged 2 to 5 years with mild to moderate atopic dermatitis, according to an Arcutis Biotherapeutics press release.

Arcutis Biotherapeutics has submitted a supplemental new drug application to the FDA for roflumilast cream 0.15% for mild to moderate atopic dermatitis treatment in adults and children aged 6 years and older, according to a press release.

Children and adults with atopic dermatitis are at an increased risk for inflammatory bowel disease, ulcerative colitis and Chron’s disease, according to a study.

The demand for cosmetic enhancement procedures is on the rise among adolescents, with 229,740 performed among this population in 2020 alone, according to a study published in the Journal of the American Academy of Dermatology.

Children and adolescents with atopic dermatitis treated with long-term dupilumab showed positive results and acceptable safety, according to a meta-analysis of multiple studies.

Greater atopic dermatitis severity correlated with greater disease burden in children and adolescents in Japan, according to a study.